Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Long-Term Investments (2021 - 2022)

ARS Pharmaceuticals (SPRY) has disclosed Long-Term Investments for 2 consecutive years, with $24.2 million as the latest value for Q2 2022.

  • Quarterly Long-Term Investments changed N/A to $24.2 million in Q2 2022 from the year-ago period, while the trailing twelve-month figure was $24.2 million through Jun 2022, changed N/A year-over-year, with the annual reading at $64.8 million for FY2021, N/A changed from the prior year.
  • Long-Term Investments hit $24.2 million in Q2 2022 for ARS Pharmaceuticals, down from $44.0 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $64.8 million in Q4 2021 to a low of $24.2 million in Q2 2022.